OncoCyte (NASDAQ:OCX – Get Free Report) and StageZero Life Sciences (OTCMKTS:SZLSF – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.
Analyst Ratings
This is a breakdown of current recommendations for OncoCyte and StageZero Life Sciences, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| OncoCyte | 0 | 2 | 2 | 0 | 2.50 |
| StageZero Life Sciences | 0 | 0 | 0 | 0 | N/A |
OncoCyte currently has a consensus price target of $7.31, suggesting a potential upside of 132.14%. Given OncoCyte’s higher possible upside, research analysts clearly believe OncoCyte is more favorable than StageZero Life Sciences.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| OncoCyte | $960,000.00 | 27.04 | -$72.90 million | N/A | N/A |
| StageZero Life Sciences | $3.80 million | 1.30 | -$11.41 million | ($0.11) | -0.36 |
StageZero Life Sciences has higher revenue and earnings than OncoCyte.
Profitability
This table compares OncoCyte and StageZero Life Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| OncoCyte | N/A | -55.56% | -25.03% |
| StageZero Life Sciences | -385.86% | N/A | -444.75% |
Risk and Volatility
OncoCyte has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500. Comparatively, StageZero Life Sciences has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500.
Summary
OncoCyte beats StageZero Life Sciences on 6 of the 9 factors compared between the two stocks.
About OncoCyte
OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, biopharma, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
About StageZero Life Sciences
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company's lead product is Aristotle, a mRNA-based multi-cancer panel test for for the detection of multiple discrete cancers from a single sample of blood. It also offers ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer; Prostate Health Index, a screening test for prostate cancer; BreastSentry, a test to determine a woman's risk for developing breast cancer; and COVID-19 Tests. The company is based in Richmond Hill, Canada.
Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.
